Who Will Really Benefit?
Myriad Genetic Laboratories is doing a direct-to-consumer marketing campaign of their test for BRCA1 and BRCA2 genetic mutations. These mutations indicate a higher than average risk for breast and ovarian cancers, which if known, would give women the chance to consider preventative treatments and changes in lifestyle. About 10%, or one in 400 women, have the BRCA gene mutation. The BRCAnalysis test could cost you from $300 to $3000, depending on what your insurance will cover, and what level of genetic sequencing needs to be done.
Should everybody have this test? The Connecticut Attorney General's office is looking closely at the claims made in the Myriad ads. Health professionals have complained that the test has a "very high potential for misinterpretation and overreaction." Alan Guttmacher, deputy director of the National Human Genome Research Institute, said that "with BRCA1 and 2, people can get uncertain test results. What do you do with that information?" Myriad admits that there is a need for more extensive testing, as well as trained genetic counselors to handle the increased demand as a result of the marketing campaign.

• Myriad Genetic Launches Direct-to-Consumer Advertising of Breast Cancer Gene Test in Northeastern Cities
• A Genetic Test That Very Few Need, Marketed to the Masses
• Breast Cancer, Colon Cancer, and Increased Risk